Background {#Sec1}
==========

Congenital malaria is usually defined as the detection of asexual forms of *Plasmodium* spp. in a blood sample of a neonate during the first week of life or later if there is no possibility of postpartum infection by a mosquito bite (out of malaria endemic area) \[[@CR1]\]. Congenital malaria can be acquired by transmission of parasites from the mother to child during pregnancy or perinatally during labour \[[@CR2]\]. Congenital malaria in endemic countries is considered a rare condition due to the protective factors as the protection supplied by the placenta, the passive transfer of maternal antibodies \[[@CR3]\] and the protective effect of fetal haemoglobin \[[@CR4], [@CR5]\]. The incidence of congenital malaria is highly variable. The literature reported an incidence between 7 and 33% in endemic area \[[@CR6], [@CR7]\] with an apparent increasing rate during the last years as result of rising drug resistance, increasing virulence of the parasite, human immunodeficiency virus (HIV) infection \[[@CR7], [@CR8]\]. The high variability seems related to several factors such as the different diagnostic methods and sampling (cord blood vs peripheral blood) used to detect *Plasmodium* spp., and the area in which the epidemiologic analyses are performed \[[@CR6], [@CR9]\]. In non-endemic countries, cases of congenital malaria are rare: in Europe only one case of congenital *Plasmodium falciparum* malaria was reported in 2014 \[[@CR10]\]; in the USA only 81 cases of congenital malaria were identified between the years 1966 and 2005 \[[@CR11]\]. Hereby, the case of a congenital malaria in an HIV-exposed child is reported.

Case presentation {#Sec2}
=================

A 2-month-old male child was admitted to the Academic Department of Pediatrics of the Bambino Gesù Children's Hospital (BGCH) due to anaemia and exposure to HIV. He was born prematurely in Italy by cesarean section at 34 weeks' gestation after a bicorial, biamniotic pregnancy with birth weight of 2.080 kg. He was the first of non-identical twins. The mother was a 30-year-old migrant woman from Nigeria, who arrived in Italy at 27 weeks gestation. At presentation, she tested seropositive for HIV and cytomegalovirus (CMV) and started antiretroviral therapy. Her absolute lymphocyte count was 1410/µl; CD4 count and the HIV viral load were not reported in the documentation received from the Hospital where the mother was admitted in emergency when she arrived in Italy.

The twins were tested for HIV at birth with PCR for HIV-RNA searching. The female twin was positive for HIV and CMV infection, while the male twin was HIV negative at birth and treated with zidovudin as post-exposure prophylaxis for 6 weeks. TORCH screening (toxoplasmosis, rubella, cytomegalovirus, herpes simplex), abdominal and cerebral ultrasounds were performed to exclude other congenital infections on both twins. A week before admission at our Department the male twin was admitted to another hospital due to anaemia (Hb 5.1 g/dl), hence receiving a blood transfusion. On initial evaluation at BGCH, he was in good general condition, weighed 3.910 kg, with temperature of 36.5 °C, heart rate of 135 beats per minute, respiratory rate of 35 for minute. His abdomen was soft, the liver was palpable 4 cm below the right costal margin. The findings of the rest of the examination were unremarkable.

Laboratory tests at the admission, after a week from the first blood transfusion, revealed a leukocyte count of 12.000/mm^3^; a haemoglobin (Hb) level of 9.1 g/dl; a platelet count of 198.000/mm^3^ and a reticulocyte count of 169.000/mm^3^. His bilirubin level was 1.31 g/dl with direct bilirubin of 0.64 mg/dl; lactate dehydrogenase level of 945 UI/L and normal renal and liver function values.

A myelosuppression effect due to the zidovudin was initially hypothesized, then the haemoglobin concentration was monitored and a supportive therapy with folic acid and iron *per os* was started.

During hospitalization, a progressive decrease of Hb levels to 6.8 g/dl was observed, therefore, requiring additional blood transfusions. Causes of haemolytic anaemia and blood loss were excluded, due to persistently high reticulocyte count; also, direct and indirect Coombs and faecal occult blood tests were performed, resulting all of which were negative. Haemoglobin electrophoresis was also performed, although in the presence of blood transfusions, to exclude hereditary haemoglobinopathies. A subsequent physical examination was then performed, revealing an increase of spleen enlargement, also confirmed by ultrasound examination. A diagnostic of malaria was then considered.

Because of the infants' age and the origin of the mother who came from an endemic area for malaria, the malaria panel provided in BGCH was performed on twins and mother's blood. The panel included the following routine algorithm: (i) Rapid diagnostic test (RDT); (ii) microscopy of Giemsa-stained thick and thin blood smears for *Plasmodium* spp. identification (ID) and parasitaemia index assigned by two independent microscopists; (iii) molecular screening and typing of *Plasmodium* spp. by an end-point multiplex qualitative polymerase chain reaction (PCR) assay.

The RDT, based on either *Plasmodium* spp. lactate dehydrogenase (pLDH) and *P. falciparum* histidine-rich protein 2 (HRP2) antigens, was performed by using SD Bioline Malaria Antigen P.f/Pan (Standard Diagnostic), whose performance is periodically monitored by the World Health Organization Malaria Control Programmes \[[@CR12]\].

Briefly, about PCR assay, DNA was extracted from 200 μl of EDTA blood with the QIAamp DNA Mini Kit (QIAGEN) and 5 μl of each DNA sample were probed with the 18S rRNA gene target of the multiplex PCR STAT-NAT Malaria Screening and Typing (Sentinel-Diagnostics). PCR products were visualized using 2.2% agarose (Lonza FlashGel^®^System) and a UV trans-illuminator BioRad.

The RDT for *Plasmodium* spp. was negative for mother and female infant specimens, while male infant resulted positive (Fig. [1](#Fig1){ref-type="fig"}). PCR analysis confirmed a positive result for mother and male twin, revealing a *P. falciparum* infection, while samples from the other twin were consistently negative with both techniques (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Thick and thin blood films stained by Giemsa revealed trophozoite forms of *P. falciparum* with parasitaemia index of 1% for the male infant and \< 1% for the mother. The RBCs of the mother infected with malarial parasites were of normal size and poly-parasitized by trophozoites (Fig. [4](#Fig4){ref-type="fig"}).Fig. 1Pattern of RDT for the mother (**a**), the male twin (**b**), the female twin (**c**) Fig. 2*Plasmodium* spp. screening by 18S rRNA targeting PCR. M DNA marker, (1/2) Mother's sample replicates; (3/4) male infant's sample replicates; (5/6) female infant's sample duplicates; (7/8) male infant's sample duplicates Fig. 3*Plasmodium falciparum* typing by 18S rRNA targeting PCR. M DNA marker, (1) Mother's sample; (2) male infant's sample Fig. 4Infant and maternal blood smears. **A**--**C** Mother's thin blood smear revealing *P. falciparum* immature trophozoites (ring forms) within erythrocytes. **D**, **E** Infant's thin blood smear, obtained on the day of delivery, documenting the presence of *P. falciparum* trophozoites within erythrocytes

Genotyping of *Plasmodium* spp. isolates was carried out to identify infectious clones in both mother and infant. The genotyping was performed by amplification of a neutral microsatellite marker (MS-TA109) \[[@CR13]\] and four highly polymorphic markers: *P. falciparum* merozoite surface protein 1 (*Pfmsp1*) and its allelic subfamilies (K1, RO33, MAD20) \[[@CR14]\], *P. falciparum* merozoite surface protein 2 (*Pfmsp2*) and its allelic subfamilies (3D7, FC27) \[[@CR14]\], *P. falciparum* histidine-rich protein 2 (*Pfhrp2*) and t *P. falciparum* histidine-rich protein 3 (*Pfhrp3*) \[[@CR15]\]. For allele detections, PCR was done in a 25 μl PCR mixture containing 10 μl of extracted DNA, 1× of MgCl~2~ free buffer Fast Start Roche, 2 mM of MgCl~2~, 200 μM of dNTPs, 10 μM of each primer and 0.25 U of FastStart Taq polymerase Roche. The cycling conditions for *Pfmsp1* were as follows: denaturation at 95 °C for 5 min, followed by 45 cycles at 94 °C for 30 min, annealing at 47 °C for 45 s and extension at 72 °C for 1.5 min and a final extension at 72 °C for 5 min. The cycling conditions for *Pfmsp1/Pfmsp2* families were: 95 °C for 5 min followed by 45 cycles at 94 °C for 1 min, 55 °C for 45 s, 72 °C for 1.5 min, and a final extension at 72 °C for 5 min. The *Pfhrp3* gene, FC27, K1 and TA109 microsatellites were amplified as described in Menegon et al. and Anderson et al. \[[@CR13], [@CR16]\]. The amplification products were analysed using a high-resolution capillary electrophoresis (QIAxcel Advanced system, Qiagen).

Genotypic characterization of *P. falciparum* isolates showed the presence of a single isolate in each of the analysed blood samples. All five *P. falciparum* polymorphic markers were genotyped for isolate present in the newborn's infection, whereas only four markers (Ta109, *Pfmsp1*, *Pfmsp2* and *Pfhrp3*) were successfully amplified for the maternal isolate. Both isolates belonged to the K1 and the FC27 allelic subfamilies. The comparison of allelic profiles, based on length polymorphism of analysed markers, showed dissimilar size alleles for two molecular markers, *Pfmsp2* and *Pfhrp3*, indicating that two different parasite isolates were present in the mother and child at the time of blood collection, 2 month after delivery. Moreover, the amplification failure of *Pfhrp2* gene in the maternal sample was presumable due to the *hrp2*---deletion in the isolate infecting the mother (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Electronic image of the gel displaying PCR product sizes of the six molecular markers amplified from mother and newborn DNA samples. The markers *Pfmsp2*, *FC27* (subfamily of *Pfmsp2*) and *Pfhrp3* showed discordant genotypes between the two analyzed samples

Because of the *P. falciparum* ID in the male infant, oral administration of atovaquone/proguanil (125 mg/50 mg daily for 3 days) was immediately started. The parasitaemia index on infant's blood performed after treatment confirmed the clearance of the parasites; the following blood exams revealed a normalization of Hb level.

Discussion and conclusions {#Sec3}
==========================

This is the third case of congenital malaria ensued in a HIV-infected mother in a non-endemic country \[[@CR11], [@CR17]\]. A review of congenital malaria cases in non-endemic country, by referring to a period spanning the last 40 years was included. The database mined for data searching was PubMed and the keywords used were "congenital malaria cases" and "non-endemic countries". The selected language was English. Congenital malaria is a rare disease in both non-endemic \[[@CR10], [@CR18]\] and endemic areas, the latter characterized by an incidence corresponding to 0.3--37% \[[@CR19]\]. Among the 37 cases of congenital malaria in non-endemic country reported in the last 40 years, 21 (58%) were caused by *Plasmodium vivax*, including 1 in combination with *Plasmodium malariae* and 1 with *P. falciparum*; 8 by *P. falciparum* (22%); three cases caused by *P. malariae* and 2 by *Plasmodium ovale* (Table [1](#Tab1){ref-type="table"}). Congenital malaria results from transplacental passage of parasites, which infect the infant in utero, or during delivery. Different mechanisms have been postulated: maternal transfusion into the fetal circulation, direct penetration of parasite through the chorionic villi or through premature separation of placenta \[[@CR1]\]. Rarely, maternal history of malaria may not be reported and, therefore, it cannot be considered as a criterion for the diagnosis of congenital malaria \[[@CR17]\]. Origin from endemic countries for malaria, fever during pregnancy, placental malaria and anaemia in the mother, are the main risk factors \[[@CR1], [@CR8]\].Table 1Congenital malaria cases reported in the last 40 years in non-endemic area \[[@CR16]\]Author/PMIDEndemic areaInterval timeAntenatal symptoms and treatment (if known)Age at diagnosisSymptoms at diagnosis*Plasmodium* species and parasitemiaHaemoglobin level g/dlPlatelets count/µlHIV statusTreatmentCountry of diagnosisVernes et al. 1978\
PMID: 353713Cambodia2 monthsF 1 day after delivery20 daysF*P. vivax*NormalNormalUnknownChloroquineFranceExcler et al. 1980\
PMID: 6987619Cambodia1 yearF1 dayF, liver and spleen enlargement*P. vivax*8172,000UnknownChloroquineFranceLajarrige\
PMID: 18307546AsiaUnknownDelivery at home12 daysF, paleness, LSE*P. vivax*3.8159,000UnknownChloroquineFranceBour´ee et al. 1983\
PMID:6340844Cameroon15 daysFBirthLack of reactivity*P. falciparum*Unknown85,000UnknownUnknownFranceCh´eron et al. 1986\
PMID:3813804Guinea7 monthsMalaria during pregnancy19 daysF*P. ovale*10134,000UnknownChloroquineFrancePeigne et al. 1987\
PMID:3318635Pakistan4 daysMalaria 4 days after delivery50 daysF, LSE, neurological*P. vivax*4.312,000UnknownChloroquineFrancePoirrier\
PMID:18307546Madagascar17 monthsF/chloroquine19 daysF*P. vivax* 1.3%6.1188,000UnknownChloroquineFranceLigny et al. 1989\
PMID:2696411Mali18 daysMalaria during pregnancy28 daysPaleness, LSE*P. falciparum* 1.5%5.2UnknownUnknownChloroquineFranceHennequin et al. 1991\
PMID:1819395Cameroon15 daysFBirthLSE, lethargy*P. falciparum* 0.1%UnknownUnknownUnknownChloroquineFranceRomand et al. 1994\
PMID:8078837Togo14 monthsF60 daysF, paleness, LSE*P. falciparum*6.3UnknownUnknownHalofantrineFranceNiyongabo et al. 1989\
PMID:2654272Laos2 yearsQuinine19 daysF, haemolysis, irritability*P. vivax* and *P. malariae*10.860,000UnknownQuinine and chloroquineFranceHindi and Azimi. 1980\
PMID:7005857Nigeria1 yearMalaria during pregnancy35 daysF, anaemia, LSE*P. falciparum*8.7257,000ngChloroquineCaliforniaPark et al. 1984\
PMID:12891034Africa0Malaria during pregnancy39 daysF, poor feeding, paleness, LSE*P. vivax* 1%12.645,000ngChloroquineKoreaGouyon et al. 1986\
PMID:3530172Guyana6 monthsMalaria during pregnancy/4-aminoquinolein21 daysF, poor feeding, paleness, LSE*P. vivax* 1%12.645,000ngChloroquineFranceLynk and Gold 1989\
PMID:2594448India (two cases)6 months, 13 monthsF during third trimester28 days, 35 daysIrregular F, anorexia and lethargy, LSE, anaemia and thrombocytopeaenia*P. vivax*4.1 and 5.947,000UnknownChloroquineCanadaJoffe and Jadavji 1990\
PMID:2196518India (two cases)9 monthsMalaria (*P. vivax*) during pregnancy/chloroquine21 daysF, diarrhoea, poor feeding, LSE, anaemia neutropenia and thrombocytopaenia*P. vivax*157,000UnknownChloroquineCanadaSubramanian et al. 1992\
PMID:1520785Salvador4 monthsF/antibiotics15 daysF, coryza, anaemia*P. vivax*Unknown52,000UnknownChloroquineTexasHulbert 1992\
PMID:1576289Guatemala1 yearAsthenia30 daysF, LSE, diarrhoea, anaemia*P. vivax*6.670,000UnknownChloroquineCaliforniaAlves 1995\
PMID:14689015Brazil40 daysUnknown14 daysUnknown*P. vivax*UnknownUnknownUnknownUnknownSão Paulo StateLee et al. 1996\
PMID:9046213PakistanUnknownF/Ibuprofen60 daysF, anaemia, haemolysis, cough, paleness, LSE*P. vivax*5.369,000ngChloroquineSingaporeMarques et al. 1996\
PMID:14688962Brazil (two cases)UnknownMalaria during pregnancyUnknownAnaemia, LSE*P. vivax, P. falciparum*UnknownUnknownUnknownunknownSão Paulo stateKuyucu et al.1999\
PMID:10770683TurkeyUnknownF and chills/Chloroquine19 daysF, poor feeding, haemolysis, anaemia, LSE*P. vivax*8.550,000ngChloroquineTurkeyNiederer and Loeffler 1999\
PMID:9951993India1 yearUnknown23 daysF, cough, irritability, poor feeding, anaemia, leucopaenia, thrombocytopaenia*P. vivax*10.727,000UnknownChloroquineCaliforniaRomero Urbano et al. 2000\
PMID:11003930Guinea1 monthUnknown21 daysF, anaemia, thrombocytopenia*P. falciparum*UnknownUnknownUnknownMefloquineSpainZenz et al. 2000\
PMID:10890139Ghana18 monthsUnknown56 daysF, LSE, anaemia*P. falciparum* and *P. malariae*8.3UnknownUnknownChloroquineGermanyD'avanzo\
MMWR, March 1, 2002/51(08); 16-5Congo5 yearsMalaria 5 years before pregnancy/chloroquine21 daysF, dark urine, respiratory troubles, anaemia*P. malariae*6.6109,000ngChloroquineNorth Carolina, USAOlowu et al. 2002\
PMID:12221966NigeriaUnknown8 hunknownunknownUnknownUnknownUnknownChloroquineOsun State, NigeriaDoraiswamy\
CDC-MMRW\
April 22, 2005/54(15);383--384Guatemala5 monthsF, coryza49 daysModerate F, anaemia*P. vivax*6.2UnknownUnknownChloroquineNew York, USASiriez et al. 2005\
PMID:16465819Congo2 yearsUnknown42 daysF, haemolysis, anaemia, thrombocytopaenia, poor feeding, LSE*P. malariae* 3%5.8110,000HIV-1ChloroquineFranceDel Castillo et al. 2017\
PMID:28077745Nigeria3 monthsPueperal F, thrombocytopenia during delivery14 daysF, cough*P. falciparum* 5.4%UnknownUnknownUnknownQuinidine and ClindamycinWashington (Columbia)Del Punta et al. 2010\
PMID:20193072Pakistan1 yearF, anaemia, thrombocytopenia during delivery22 daysF, paleness, whining cry, liver and spleen enlargement,*P. vivax* 2%12.314,000UnknownChloroquineItalyVoittier et al. 2008\
PMID:18307546Guyana6 monthsmalaria *P. vivax*/4-aminoquinoline21 daysF, paleness, liver and spleen enlargement*P. vivax* 1%12.645,000UnknownChloroquineFranceVoittier et al.2008\
PMID:18307546Angola3 yearsHIV19 daysF, poor feeding*P. ovale* 2%1238,000ngChloroquineFranceHagmann et al. 2007\
PMID:17505278Honduras9 monthsMalaria during pregnancy26 daysF, cough, runny nose*P. vivax* 4--5%11.4313,000UnknownChloroquineNew York, USADe Pontual et al. 2006\
PMID:17030531Congo2 yearsHIV42 daysF, liver and spleen enlargement*P. malariae* 1.8%6.4122,000ngChloroquineFranceHewson et al. 2003\
PMID:14629507India4 monthsF, abdominal pain, rigors19 daysApnoea, bradycardia*P. vivax*12.295,000UnknownChloroquineSouth Australia*F* fever, *LSE* liver spleen enlargement, *ng* negative

HIV infection increases susceptibility to malaria during pregnancy \[[@CR7]\] and it is associated with higher parasite density, higher risk of maternal and fetal anaemia, intra-uterine growth retardation (IUGR) and pre-term delivery \[[@CR20]\], and low birth weight (LBW) in the neonates \[[@CR21]\]. Recently a higher prevalence of congenital malaria in infants of mothers co-infected with HIV and malaria have been reported \[[@CR8]\]. HIV infection compromised maternal immunity though an impairment of antibody responses with a higher risk of *P. falciparum* transmission \[[@CR22]\]. However, the mechanism by which HIV increases susceptibility to malaria is not known. After birth, the mother may have a normal physical examination and negative blood malaria parasite \[[@CR17]\]. In the present case, the mother never suffered from fever or symptoms suggestive for malaria during pregnancy. In women from endemic countries for malaria and with previous episodes of malaria it is common to be asymptomatic because of the immunity developed during the time \[[@CR23]\].

In most cases of congenital malaria, the diagnosis is made at 10--28 days of age; 20 of the 37 published cases (56%) were diagnosed before 21 days (Table [1](#Tab1){ref-type="table"}). The symptoms are rarely detected at birth, possibly because of the presence of IgG transferred from the mother during the pregnancy, and the protective effect of HbF; indeed, the passive immunity may prevent delay the onset of congenital malaria up to 6 weeks \[[@CR24]\].

Clinical features of congenital malaria include fever, anaemia, thrombocytopaenia, liver and spleen enlargement. Jaundice, regurgitation, loose stools and poor feeding, occasionally apnea and cyanosis have also been reported \[[@CR1]\]. Such clinical features may be confused with bacterial or viral infection, leading to a delay in diagnosis \[[@CR25]\]. The patient presented anaemia with high level of reticulocyte. He needed a blood transfusion every week, a progressive spleen enlargement was noted. Initially toxicity by antiretroviral therapy was hypothesized because of the good clinical condition and the absence of symptoms and signs suggestive for infection. No fever was detectable during the entire hospitalization. Five other cases of congenital malaria without fever have been described (Table [1](#Tab1){ref-type="table"}). In this case, there was not record of the exact onset of anaemia because blood tests were not performed during the period 7--30 days after birth. Likely, the anaemia occurred days and even weeks before admission to hospital.

The mother of the infant travelled during pregnancy in region where a high percentage of *P. falciparum* chloroquine resistance is reported, finally arriving to a non-endemic country \[[@CR26], [@CR27]\]. Because of the stable clinical condition and for the suspect of chloroquine resistance, the authors decided to treat the infant, with atovaquone/proguanil according to CDC guidelines \[[@CR28]\]. Because the parasitaemia index was 1% and no criteria of severe malaria were present, oral administration was considered as appropriate treatment. *Plasmodium* spp. on female twin's blood was absent, as reported for other cases in the literature \[[@CR29]--[@CR36]\]. Peripheral maternal and peripheral newborn's parasite populations was analysed 2 month after delivery to compare allelic profile of persistent *P. falciparum* isolates. Two different parasite isolates in the mother and child at the time of blood collection were found. Likely during the gestation the mother was parasitized by different *P. falciparum* strains, as supported by literature data \[[@CR37]\]. It is conceivable for the mother to have harboured more than one isolate during pregnancy, only one of them being transmitted to the newborn and the different one having persisted in the mother's blood after delivery \[[@CR38]\].

Malaria RDTs are useful tools to confirm presence of malaria. Under optimal conditions, the sensitivity of the RDTs is considered similar to that of direct microscopy \[[@CR39]\]. However, their execution may be questionable since on a number of occasions false negative results have been encountered which would negatively affect proper early therapeutic intervention. The three main groups of antigens detected by RDTs are HRP2, produced by trophozoites and young gametocytes of *P. falciparum* only; pLDH enzyme (*P. falciparum* specific, *P. vivax* specific or pan specific), and aldolase pan-specific enzyme \[[@CR40]\].

In the presented case, RDTs of peripheral blood failed to detect a maternal infection, while PCR and microscopy were highly effective. PfHRP2 is a histidine and alanine-rich protein, characterized by a highly polymorphic repeat domain and represents the most common malaria antigen targeted by RDTs for the specific diagnosis of *P. falciparum* \[[@CR41]\]. Frequently, another protein of *P. falciparum*, the PfHRP3 antigen \[[@CR42]\], is recognized by PfHRP2-based RDTs \[[@CR40], [@CR43]\]. The above studies further revealed that polymorphisms of the *Pfhrp*2/3 genes can affect the performance of HRP2-based RDTs in term of sensitivity up to total test failure (false-negative), recommending molecular investigation. False negatives can be also due to impairment in host and parasite density, or antigen concentration.

Finally, *P. falciparum* parasites not expressing PfhHRP2 and/or PfHRP3 antigens have been reported \[[@CR44]\]. These results are consistent with those reported in the literature \[[@CR45]--[@CR49]\], and suggest that diagnostic guidelines for malaria be revisited.

The negative RDT in the mother can be justified by a low parasitaemia index and by the possible deletion of the *Pfhrp*2 gene in this parasite. As in the present case, the discordance in vertical transmission of malaria in bicorial and biamniotic pregnancy is reported in the literature \[[@CR29]\], as well for CMV, HIV and toxoplasmosis \[[@CR32], [@CR33], [@CR35]\]. Therefore, the same pathogenesis was supposed for the present case.

Conclusion {#Sec4}
==========

A prompt diagnosis of congenital malaria is crucial. The increasing number of pregnant women travelling from endemic areas for malaria to non-endemic countries, calls for routine investigation of *Plasmodium* spp. in women and neonates at risk: (i) women and pregnant women from endemic area for malaria, (ii) all neonates and infants with fever, anaemia, thrombocytopaenia and hepatosplenomegaly with mother who have travelled or lived in non-endemic area for malaria (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Hypothesis of diagnostic algorithm for congenital malaria. Asterisk If PCR for *Plasmodium* spp is available in the Hospital

In such cases, accurate anamnesis of neonate's mother and inclusion of *Plasmodium* spp. search into the TORCH screening for mother and infant at birth should be performed, to avoid delay in the diagnosis and to reduce morbidity and mortality associated to the disease. The differential diagnosis between neonatal malaria vs neonatal sepsis is not easily to be resolved by the use of clinical features alone. However, also the laboratory diagnosis of low parasitaemia, such as that observed in mother-infant pair infections, require high level of expertise in malaria diagnostic panels. Use of malaria RDT assays that can detect antigens other than PfHRP2 and pLDH should could be strongly encouraged in field setting but also in hospitals, in order to enhance malaria diagnosis. Advanced malaria diagnostic panels, when possible, can be decisive to monitor both congenital and other malaria infections during perinatal and paediatric ages.

HIV

:   human immunodeficiency virus

TORCH

:   toxoplasmosis, rubella, cytomegalovirus, herpes simplex

RDT

:   rapid diagnostic test

LDH

:   lactate dehydrogenase

hrp2

:   histidine-rich protein 2

MS-TA109

:   microsatellite-(TA)n

*Pfmsp1*

:   *Plasmodium falciparum* merozoite surface protein 1

*Pfmsp2*

:   *Plasmodium falciparum* merozoite surface protein 2

*Pfhrp3*

:   *Plasmodium falciparum* histidine-rich protein 3

LBW

:   low birth weight

IUGR

:   intra-uterine growth retardation

WHO

:   World Health Organization

All authors have made substantial contributions to the investigations presented in this manuscript. PP and LP made the diagnosis, supervised all data collection and participated in drafting the manuscript; LR drafted the manuscript; SB, PP and HT clinically followed-up the mother and the child, SP, MM, GF, LP and CS carried out the molecular and genotyping studies. SP, SB, MM, CS, HT and AOM, revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

We want to thank the patient who participated in this study, and the staff of Fondazione Siniscalco Ceci Emmaus Onlus. We thank Valeria Marzano for advice in figure preparation.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

Upon request emoscopic and DNA materials are available.

Consent for publication {#FPar4}
=======================

A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate {#FPar5}
==========================================

Written informed consent was obtained from the mother for her participation and that of her baby for the publication of this case report.

Funding {#FPar6}
=======

This study was supported by internal grant from "Bambino Gesù Children's Hospital" (RC 2018) to Paolo Palma and by CCM 2015 AMR to Lorenza Putignani ([http://www.ccm-network.it/pagina.jsp?id=node/2075&idP=740&idF=1870](http://www.ccm-network.it/pagina.jsp%3fid%3dnode/2075%26idP%3d740%26idF%3d1870)).

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
